Insider activity on CHRD over the last 12 months.
Price & insider trades
Where insiders bought and sold against CHRD's price — tap a bubble for the P&L since.
Graded signals
AI-scored insider events on CHRD — tap any signal for the full read.
BEARISHCHRD EVP Sells $1.4M Stake at $140.42 Amid Strong Buy Consensus28d ago
Lou Michael H sold $1.4M worth of CHRD shares at $140.42, reducing his direct holdings by 12.1% at a price 6.8% below the 90-day high. This sale continues his established pattern of selling with no prior buys, though it occurs against a backdrop of strong analyst consensus and 13 days before earnings. Our 7-8 conviction officer sells historically underperform SPY by 8.0% at 30 days; watch for a break below $111.25 to confirm bearish momentum.
Where it could go — Our 7-8 conviction officer sells: 36% beat SPY at 30d; bear breaks $111.25.
NEUTRAL30d -13.6% vs SPYCHRD EVP sells $186K near 90-day high in first-ever trade94d ago
EVP Darrin Henke sold $186,000 in CHRD shares, reducing his stake by 5.7% at a price just 3.0% below the 90-day high. This first-time sale near a recent peak lacks a supporting cluster of other buyers, making it more likely routine than a strong directional signal.
Where it could go — Analyst mean target not provided; bear case if stock breaks the 30-day low of $119.92.
NEUTRAL30d +0.2% vs SPYBrooks Douglas E sells 3,000 CHRD shares at $137.79; first trade on file101d ago
Director Brooks Douglas E executed a Code-S open-market sale of 3,000 shares at $137.79 on 2026-05-07, reducing holdings by 11.2% ($413K notional value). This is the insider's first Form 4 filing on record—no prior Code-P buys or Code-S sales exist, eliminating any historical pattern baseline for this individual. The sale occurred 43% above the 90-day low ($96.39) and 8.4% below the 90-day high ($150.50), with 25 analysts maintaining STRONG BUY consensus (21 buy / 4 hold / 0 sell), and zero other insider buyers in the past 60 days.
Where it could go — Without prior trading history for this insider or comparable CHRD Code-S signals in the dataset, directional conviction is low; if the analyst consensus holds and no material negative catalyst emerges, the stock's historical support near $120 (30d low) would need to break to invalidate the bull case implied by 84% buy-side coverage.
NEUTRAL30d -1.8% vs SPYBrooks Douglas E sells 3,000 CHRD shares at $137.79; first trade on file101d ago
Director Brooks Douglas E executed a Code-S open-market sale of 3,000 shares at $137.79 on 2026-05-07, reducing holdings by 11.2% ($413K notional value). This is the insider's first Form 4 filing on record—no prior Code-P buys or Code-S sales exist, eliminating any historical pattern baseline for this individual. The sale occurred 43% above the 90-day low ($96.39) and 8.4% below the 90-day high ($150.50), with 25 analysts maintaining STRONG BUY consensus (21 buy / 4 hold / 0 sell), and zero other insider buyers in the past 60 days.
Where it could go — Without prior trading history for this insider or comparable CHRD Code-S signals in the dataset, directional conviction is low; if the analyst consensus holds and no material negative catalyst emerges, the stock's historical support near $120 (30d low) would need to break to invalidate the bull case implied by 84% buy-side coverage.
NEUTRAL30d -1.6% vs SPYBrooks Douglas E sells 3,000 CHRD shares at $137.79; first trade on file101d ago
Director Brooks Douglas E executed a Code-S open-market sale of 3,000 shares at $137.79 on 2026-05-07, reducing holdings by 11.2% ($413K notional value). This is the insider's first Form 4 filing on record—no prior Code-P buys or Code-S sales exist, eliminating any historical pattern baseline for this individual. The sale occurred 43% above the 90-day low ($96.39) and 8.4% below the 90-day high ($150.50), with 25 analysts maintaining STRONG BUY consensus (21 buy / 4 hold / 0 sell), and zero other insider buyers in the past 60 days.
Where it could go — Without prior trading history for this insider or comparable CHRD Code-S signals in the dataset, directional conviction is low; if the analyst consensus holds and no material negative catalyst emerges, the stock's historical support near $120 (30d low) would need to break to invalidate the bull case implied by 84% buy-side coverage.
Recent insider trades
The open-market buys and sells filed on CHRD.